IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL

Results in Immunology

Volumn 2, Issue , 2012, Pages 13-18

  Fiskesund, Roland ^a   Su, Jun ^a   Bulatovic, Ivana ^a   Vikström, Max ^a   de Faire, Ulf ^a,b   Frostegård, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Apoptosis; Biomarkers; Carotid intima media thickness; Phosphorylcholine

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A PHOSPHORYLCHOLINE ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 PHOSPHORYLCHOLINE ANTIBODY; IMMUNOGLOBULIN G2 PHOSPHORYLCHOLINE ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN M PHOSPHORYLCHOLINE ANTIBODY; LACIDIPINE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MALONALDEHYDE; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY BIFURCATION; CELL DEATH; COMMON CAROTID ARTERY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84856039923     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.01.001     Document Type: Article

References (38)

1. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 473:317-25.
2. Frostegard J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
3. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clinical Reviews in Allergy & Immunology 2009, 37:4-11.
4. Holvoet P., Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 1998, 137:S33-S38.
5. Hjerpe C, Johansson D, Hermansson A, Hansson GK, Zhou XH. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(-/-) mice. Atherosclerosis 209:436-41.
6. Subbanagounder G., Leitinger N., Shih P.T., Faull K.F., Berliner J.A. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis-in vitro and in vivo inhibition by WEB 2086. Circulation Research 1999, 85:311-318.
7. Matsumoto T., Kobayashi T., Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Current Medicinal Chemistry 2007, 14:3209-3220.
8. Marathe G.K., Harrison K.A., Murphy R.C., Prescott S.M., Zimmerman G.A., McIntyre T.M. Bioactive phospholipid oxidation products. Free Radical Biology and Medicine 2000, 28:1762-1770.
9. Choi J, Zhang WJ, Gu XD, Chen X, Hong L, Laird JM, et al. Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids. Chemical Research in Toxicology 24:111-8.
10. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. Journal of Clinical Investigation 2000, 105:1731-1740.
11. Berliner J.A., Subbanagounder G., Leitinger N., Watson A.D., Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends in Cardiovascular Medicine 2001, 11:142-147.
12. Renu Virmani J.N., Leon Martin B., Willerson James T. The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management 2006, Wiley-Blackwell. first ed.
13. Chen Y.F., Park Y.B., Patel E., Silverman G.J. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. Journal of Immunology 2009, 182:6031-6043.
14. de Faire U, Su J, Hua X, Frostegard A, Halldin M, Hellenius ML, et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. Journal of Autoimmunity 34:73-9.
15. Chou M.Y., Fogelstrand L., Hartvigsen K., Hansen L.F., Woelkers D., Shaw P.X., et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. Journal of Clinical Investigation 2009, 119:1335-1349.
16. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nature Medicine 2003, 9:736-743.
17. Faria-Neto J.R., Chyu K.Y., Li X., Dimayuga P.C., Ferreira C., Yano J., et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006, 189:83-90.
18. Caligiuri G., Khallou-Laschet J., Vandaele M., Gaston A.T., Delignat S., Mandet C., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. Journal of the American College of Cardiology 2007, 50:540-546.
19. Nishinarita S., Sawada S., Horie T. Phosphorylcholine antibodies in pulmonary infection. Medical Microbiology and Immunology 1990, 179:205-214.
20. Brown M., Schiffman G., Rittenberg M.B. Subpopulations of antibodies to phosphocholine in human serum. Journal of Immunology 1984, 132:1323-1328.
21. Su J., Georgiades A., Wu R., Thulin T., de Faire U., Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006, 188:160-166.
22. Fiskesund R., Stegmayr B., Hallmans G., Vikstrom M., Weinehall L., de Faire U., et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 41:607-12.
23. Gronlund H., Hallmans G., Jansson J.H., Boman K., Wikstrom M., de Faire U., et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. European Journal of Cardiovascular Prevention and Rehabilitation 2009, 16:382-386.
24. Sjoberg B.G., Su J., Dahlbom I., Gronlund H., Wikstrom M., Hedblad B., et al. Low levels of IgM antibodies against phosphorylcholine-a potential risk marker for ischemic stroke in men. Atherosclerosis 2009, 203:528-532.
25. Zanchetti A., Bond G., Hennig M., Neiss A., Mancia G., Dal Palu C., et al. Calcium antagonist, lacidipine slows down progression of asymptomatic carotid atherosclerosis-principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
26. Wu R.H., de Faire U., Lemne C., Witztum J.L., Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999, 33:53-59.
27. Leon M.A., Young N.M. Specificity for phosphorylcholine of six murine myeloma proteins reactive with pneumococcus C-polysaccharide and beta-lipoprotein. Biochemistry 1971, 10:1424-1429.
28. Mi Q.S., Zhou L., Schulze D.H., Fischer R.T., Lustig A., Rezanka L.J., et al. Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6031-6036.
29. Binder C.J., Shaw P.X., Chang M.K., Boullier A., Hartvigsen K., Horkko S., et al. The role of natural antibodies in atherogenesis. Journal of Lipid Research 2005, 46:1353-1363.
30. Su J., Hua X., Concha H., Svenungsson E., Cederholm A., Frostegard J. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 2008, 47:1144-1150.
31. Chou M.Y., Hartvigsen K., Hansen L.F., Fogelstrand L., Shaw P.X., Boullier A., et al. Oxidation-specific epitopes are important targets of innate immunity. Journal of Internal Medicine 2008, 263:479-488.
32. Blaizot A., Vergnes J.N., Nuwwareh S., Amar J., Sixou M. Periodontal diseases and cardiovascular events: meta-analysis of observational studies. International Dental Journal 2009, 59:197-209.
33. Schenkein H.A., Gunsolley J.C., Best A.M., Harrison M.T., Hahn C.L., Wu J.H., et al. Antiphosphorylcholine antibody levels are elevated in humans with periodontal diseases. Infection and Immunity 1999, 67:4814-4818.
34. Scott M.G., Shackelford P.G., Briles D.E., Nahm M.H. Human-IgG subclassers and their relation to carbohydrate antigen immunocompetence. Diagnostic and Clinical Immunology 1988, 5:241-248.
35. Goldenberg H.B., McCool T.L., Weiser J.N. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. Journal of Infectious Diseases 2004, 190:1254-1263.
36. Seimon T., Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. Journal of Lipid Research 2009, 50(Suppl:S382-7).
37. Portman O.W., Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. Journal of Lipid Research 1969, 10:158-165.
38. Padilla N.D., Ciurana C., van Oers J., Ogilvie A.C., Hack C.E. Levels of natural IgM antibodies against phosphorylcholine in healthy individuals and in patients undergoing isolated limb perfusion. Journal of Immunological Methods 2004, 293:1-11.